Vertex Pharmaceuticals Incorporated (VRTX)

215.01 +1.85 (+0.87%) At close: 4:00PM EDT

Vertex Pharmaceuticals Incorporated

50 Northern Avenue
Boston, MA 02210
United States
617 341 6100
http://www.vrtx.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 3,400

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Jeffrey Marc Leiden	Exec. Chairman	3.14M	36.36M	1956
Dr. Reshma Kewalramani	CEO, Pres & Director	3.86M	506.93k	1973
Mr. Charles F. Wagner Jr.	Exec. VP & CFO	1.71M	N/A	1968
Mr. Stuart A. Arbuckle	EVP, Chief Commercial & Operations Officer	2.03M	2.07M	1966
Dr. David M. Altshuler	Exec. VP of Global Research & Chief Scientific Officer	1.81M	2.03M	1965
Mr. Paul M. Silva	Sr. VP & Chief Accounting Officer	N/A	N/A	1966
Mr. Mike Tirozzi	SVP and Chief Information & Data Officer	N/A	N/A	N/A
Mr. Michael Partridge	Sr. VP of Investor Relations	N/A	N/A	N/A
Mr. Damian W. Wilmot Esq.	Sr. VP, Chief Risk and Compliance Officer	N/A	N/A	1976
Ms. Joy Liu	Sr. VP & Gen. Counsel	N/A	N/A	N/A

Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 12 years of age or older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator, or CFTR, gene. Its pipeline includes Pipeline for Alpha-1 antitrypsin deficiency that is in Phase 2 clinical trial; VX-864, a second investigational small molecule corrector for the treatment of AAT deficiency, which is in Phase 1 clinical trial; and VX-147 that completed a Phase 1 clinical trial for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG; Arbor Biotechnologies, Inc.; Moderna, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany; X-Chem, Inc.; Janssen Pharmaceuticals, Inc.; Merck KGaA; Kymera Therapeutics; Ribometrix, Inc.; Molecular Templates, Inc.; and Affinia Therapeutics, as well as a strategic research collaboration and licensing agreement with Obsidian Therapeutics, Inc. for the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts.

Corporate Governance

Vertex Pharmaceuticals Incorporated’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 2; Board: 6; Shareholder Rights: 6; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.